1-(新戊基氧基)-2-硝基苯 | 210694-00-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(新戊基氧基)-2-硝基苯
• 中文别名: 1-(2,2-二甲基丙氧基)-2-硝基苯
• 英文名称: o-neopentoxynitrobenzene
• 英文别名: 1-(Neopentyloxy)-2-nitrobenzene；1-(2,2-dimethylpropoxy)-2-nitrobenzene
• CAS: 210694-00-1
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: NHGTVPMHHZFTLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  1-(新戊基氧基)-2-硝基苯 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 sodium iodide 作用下， 以 乙醇 、 二乙二醇二甲醚 为溶剂， 反应 19.5h， 生成 1-[2-(2,2-Dimethylpropoxy)phenyl]piperazine
  参考文献：
  名称：

  N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α₁-Adrenoceptor Antagonists

  摘要：

  Novel arylpiperazines were identified as alpha(1)-adrenoceptor(BR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides,;as well as carboxamides of quinoline, I,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta;a were used as a ''negative screen'' for the test antagonists. Binding to alpha(1)-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g, 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the alpha(1)-AR subtype prevalent in the human lower urinary tract (pA(2) values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the alpha(1D)-AR.

  DOI：

  10.1021/jm970166j
• 作为产物：
  描述：

  [(+/-)-BINAP]Pd(o-C6H4NO2)(OCH2CMe3) 以103 %的产率得到1-(新戊基氧基)-2-硝基苯
  参考文献：
  名称：

  从钯（芳基）新五氧化物配合物进行 C−O 还原消除的电子依赖性

  摘要：

  钯（芳基）新五氧化物络合物的热分解 [P-P]Pd(Ar)OCH2CMe3 [P-P = Tol-BINAP 或 BINAP；Ar = p-C6H4CHO (1b), p-C6H4COPh (1c), p-C6H4NO2 (1d), o-C6H4NO2 (1e), o-C6H4CN (1f)] 在钯结合的芳基上具有适合于离域的取代基负电荷导致芳醚的定量 (≥95%) 形成而没有可检测的 β-氢化物消除。1b-f 的热分解服从一级动力学，还原消除速率按 o-NO2 > p-NO2 > p-CHO > p-COPh > o-CN 的顺序降低。相反，相关衍生物的热分解 [P-P]Pd(Ar)OCH2CMe3 [P-P = Tol-BINAP 或 BINAP；Ar = p-C6H4Cl (1g), m-C6H4NO2 (1h), m-C6H4CN (1i)] 在钯结合的芳基上不具有共振稳定基团，导致无法检测到芳醚的形成。

  DOI：

  10.1021/ja9806581

文献信息

• Imine Compound
  申请人：Saito Shiuji

  公开号：US20080312435A1

  公开（公告）日：2008-12-18

  An imine compound represented by the formula: wherein A represents a heterocyclic group; R 1 , R 2 , an R 3 each represent a hydrogen atom, a halogen atom, a C 1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom(s), a C 3-10 cycloalkyl group, a C 1-6 haloalkyl group, a C 1-10 alkoxy group, etc.; R 4 represents an optionally substituted C 1-10 alkyl, C 2-6 alkenyl, or aryl group; R 5 represents a hydrogen atom, a C 1-10 alkoxy group, a C 1-6 haloalkyl group, an optionally substituted C 1-10 alkyl or C 2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents —CO—, —CO—CO—, —CO—NH—, —CS—NH—, or —SO 2 —, or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient. The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

  一种以以下式表示的亚胺化合物：其中A代表杂环基团；R1、R2和R3分别表示氢原子、卤素原子、C1-10烷基，该烷基可选地取代有芳基，所述芳基取代有卤素原子，C3-10环烷基，C1-6卤代烷基，C1-10烷氧基等；R4表示可选地取代的C1-10烷基，C2-6烯基或芳基；R5表示氢原子，C1-10烷氧基，C1-6卤代烷基，可选地取代的C1-10烷基或C2-6烯基，可选地取代的芳基或杂环基团等；W表示—CO—，—CO—CO—，—CO—NH—，—CS—NH—或—SO2—，或以该亚胺化合物为活性成分的大麻素受体激动剂。本发明的亚胺化合物具有大麻素受体激动剂作用，可用作治疗或预防疼痛和自身免疫性疾病的药物。
• EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS
  申请人：The Regents of the University of California

  公开号：US20160244435A1

  公开（公告）日：2016-08-25

  Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to imidazole, thiazole, and furan derivatives and their use as therapeutic agents.

  本文披露了抗微生物化合物组成物、制药组合物、其使用和制备方法。其中一些实施例涉及咪唑、噻唑和呋喃衍生物及其作为治疗剂的使用。